tradingkey.logo

bioAffinity Technologies Inc

BIAF

4.980USD

+4.811+2845.00%
Close 09/19, 16:00ETQuotes delayed by 15 min
141.73MMarket Cap
LossP/E TTM

bioAffinity Technologies Inc

4.980

+4.811+2845.00%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
99 / 207
Overall Ranking
215 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Hold
Current Rating
6.000
Target Price
+2190.95%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 194820.30% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.36M.
Undervalued
The company’s latest PE is -7.15, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.91M shares, increasing 24.21% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 40.64K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.80.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.83, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.27M, representing a year-over-year decrease of 47.05%, while its net profit experienced a year-over-year decrease of 92.43%.

Score

Industry at a Glance

Previous score
6.83
Change
0

Financials

4.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.28

Operational Efficiency

10.00

Growth Potential

5.39

Shareholder Returns

7.23

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.24, which is 263.89% below the recent high of -0.88 and -585.99% above the recent low of -1.66.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for bioAffinity Technologies Inc is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts
Hold
Current Rating
6.000
Target Price
+2190.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
bioAffinity Technologies Inc
BIAF
1
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.57, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.37 and the support level at 0.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.57
Change
4.9

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(0)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MACD(12,26,9)
0.599
Buy
RSI(14)
96.314
Overbought
STOCH(KDJ)(9,3,3)
55.440
Buy
ATR(14)
0.405
High Vlolatility
CCI(14)
466.667
Overbought
Williams %R
4.906
Overbought
TRIX(12,20)
6.220
Buy
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
1.189
Buy
MA10
0.722
Buy
MA20
0.483
Buy
MA50
0.374
Buy
MA100
0.331
Buy
MA200
0.511
Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 20.77%, representing a quarter-over-quarter decrease of 31.92%. The largest institutional shareholder is The Vanguard, holding a total of 40.64K shares, representing 0.14% of shares outstanding, with 91.47% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Crumly (Richard K)
1.81M
--
Girgenti (Steven)
1.09M
--
Rubin (Gary D)
669.20K
--
The Joyce Living Trust
583.13K
+3.55%
Zannes (Maria)
383.83K
+36.95%
Anderson (Robert A)
163.94K
--
Geode Capital Management, L.L.C.
118.69K
+19.22%
Edwards (James Michael CPA)
120.13K
--
Knight (Peter S)
117.45K
--
Diamond Stuart
99.09K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.95, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.95
Change
0
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+92.24%
240-Day Volatility
+407.14%
Return
Best Daily Return
60 days
+2845.00%
120 days
+2845.00%
5 years
--
Worst Daily Return
60 days
-30.04%
120 days
-44.50%
5 years
--
Sharpe Ratio
60 days
+2.03
120 days
+1.54
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+92.24%
3 years
+94.47%
5 years
--
Return-to-Drawdown Ratio
240 days
+1.80
3 years
+0.26
5 years
--
Skewness
240 days
+15.19
3 years
+26.16
5 years
--
Volatility
Realised Volatility
240 days
+407.14%
5 years
--
Standardised True Range
240 days
+2.10%
5 years
--
Downside Risk-Adjusted Return
120 days
+5231.83%
240 days
+5231.83%
Maximum Daily Upside Volatility
60 days
+6124.39%
Maximum Daily Downside Volatility
60 days
+5395.52%
Liquidity
Average Turnover Rate
60 days
+25.41%
120 days
+48.02%
5 years
--
Turnover Deviation
20 days
-79.53%
60 days
+97.02%
120 days
+272.24%

Peer Comparison

Healthcare Equipment & Supplies
bioAffinity Technologies Inc
bioAffinity Technologies Inc
BIAF
6.00 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI